


# **2012 Cancer Program Annual Report**

Barnabas Health – Community Medical Center
J. Phillip Citta Regional Cancer Center

A statistical report of cancer cases seen at Barnabas Health - Community Medical Center (CMC) in 2012. This data is benchmarked against the National Cancer Data Base. Some of the graphical representations include a breakdown of cases by Age, Gender, Race, as well as more site specific data.



# 

## STATISTICAL SUMMARY OF CANCER CASES AT CMC

### PATIENT DEMOGRAPHICS

Data from the American Cancer Society's: Facts and Figures for 2012 estimated that there will be over 1,638,910 new cancer cases in 2012. 50,650 will be diagnosed in New Jersey.

In 2012, there were 1431 new cancer cases accessioned at Community Medical Center (CMC).

Of the 1431 cases, the non-analytic cases include 63 that were seen for recurrent or progressive disease (Classes 30-38) and 8 cases that were pathology review cases (Class 43). The following statistical report is based on the remaining 1360 analytic cases, of which, 190 were diagnosed at CMC and went elsewhere for treatment (Class 00), 834 were diagnosed and treated at CMC (Classes 10-14) and 336 were diagnosed at another facility and referred to CMC for treatment (Classes 20-22). *Figure 1* represents a breakdown by class of case.

Medicare was the primary insurance coverage for 72% of patients followed by Managed Care at 24% and 1% Medicaid.

Gender distribution revealed 59% females and 41% males. Race distribution included: White: 96%, Black: 0%, and other or unspecified race at 4%. *Figure 2* is a representation by gender and race.

### SITE DISTRIBUTION

**Figure 3** summarizes the top five analytical primary sites for 2012 which include lung, breast, colon, melanoma and prostate.




Table 1 summarizes all the primary sites for 2012 by class of case and gender.

Primary Site  ALL SITES  ORAL CAVITY & PHARYNX	Total All Cases (%)	Class of Ca Analytic (%)	NA	Se M	F	Vit Alive		c. 0			Distribu			
ORAL CAVITY & PHARYNX							EXP				Stg III	Stg IV	88	Unk
	1,431	1,360	71	563	797	1,028	332	Analyti 104	ic Cases (	229	197	214	118	113
Tongue	20 (2.0%)	27 (2.0%)	1	16	-11	18	9	0	3	3	4	13	0	4
Tongue	11 (0.8%)	11 (0.8%)	0	4	7	6	5	0	0	1	1	6	0	3
Salivary Glands	4 (0.3%)	4 (0.3%)	0	4	0	3	1	0	2	1	1	0	0	0
Floor of Mouth Gum & Other Mouth	1 (0.1%)	1 (0.1%)	0	1	0	1	0	0	0	0	0	0	0	0
Nasopharynx	3 (0.2%) 3 (0.2%)	2 (0.1%) 3 (0.2%)	0	2	i	3	0	0	0	1	0	2	0	0
Tonsil	3 (0.2%)	3 (0.2%)	0	1	2	3	0	0	0	0	1	1	0	1
Hypopharynx	3 (0.2%)	3 (0.2%)	0	3	0	1	2	0	0	0	0	3	0	0
	267 (18.7%)	257 (18.9%)	10	120	137	181	76	7	47	66	57	52	6	22
Esophagus	16 (1.1%)	16 (1.2%)	0	13	3	11	5	0	3	5	6	1	0	1
Stomach	21 (1.5%)	20 (1.5%)	1	8	12	10	10	0	2	3	6	2	0	7
Small Intestine	2 (0.1%)	2 (0.1%)	0	2	0	1	1	0	1	0	0	1	0	0
	101 (7.1%)	100 (7.4%)	1	44	56	76	24	6	17	33	24	18	0	2
Cecum	30 23	30 23	0	8 13	22 10	25 16	5 7	4	5 5	<i>7</i> 10	9	5 2	0	0
Ascending Colon Hepatic Flexure	23 4	4	0	13	3	3	1	0	1	10	1	1	0	0
Transverse Colon	9	9	0	2	7	7	2	1	1	4	2	i	0	0
Descending Colon	9	9	0	6	3	8	1	1	3	2	2	1	0	0
Sigmoid Colon	18	18	0	11	7	15	3	0	2	8	4	2	0	2
Large Intestine, NOS	8	7	1	3	4	2	5	0	0	1	0	6	0	0
Rectum & Rectosigmoid	53 (3.7%)	51 (3.8%)	2	23	28	44	7	0	19	13	10	7	0	2
Rectosigmoid Junction	23	23	0	11	12	20	3	0	6	7	5	5	0	0
Rectum	30	28	2	12	16	24	4	0	13	6	5	2	0	2
Anus, Anal Canal & Anorectum	7 (0.5%)	7 (0.5%)	0	3	4	6	1	1	0	3	2	0	0	1
Liver & Intrahepatic Bile Duct	15 (1.0%)	15 (1.1%)	0	9	6	10	5	0	2	0	2	2	4	5
Liver Intrahepatic Bile Duct	9 6	9	0	5 4	4	7 3	2	0	2	0	1	2	1	3
Gallbladder	4 (0.3%)	4 (0.3%)	0	1	3	3	1	0	0	2	1	1	0	0
Other Biliary	4 (0.3%)	3 (0.2%)	1	2	1	2	i	0	1	0	0	0	2	0
Pancreas	43 (3.0%)	38 (2.8%)	5	15	23	17	21	0	2	7	5	20	0	4
Peritoneum, Omentum & Mesentery	1 (0.1%)	1 (0.1%)	0	0	1	1	0	0	0	0	1	0	0	0
RESPIRATORY SYSTEM 2	273 (19.1%)	261 (19.2%)	12	125	136	139	122	1	57	14	68	96	1	24
Nose, Nasal Cavity & Middle Ear	1 (0.1%)	1 (0.1%)	0	1	0	1	0	0	0	0	1	0	0	0
Larynx	14 (1.0%)	14 (1.0%)	0	10	4	9	5	1	7	0	0	4	0	2
	258 (18.0%)	246 (18.1%)	12	114 7	132	129	117	0	50 <b>2</b>	14 5	67	92	1	22
SOFT TISSUE Soft Tissue (including Heart)	12 (0.8%) 12 (0.8%)	12 (0.9%) 12 (0.9%)	0	7	5	10 10	2	0	2	5	0	3	1	1
SKIN EXCLUDING BASAL & SQUAMOUS	92 (6.4%)	85 (6.3%)	7	58	27	81	4	13	58	9	1	3	0	1
Melanoma Skin	86 (6.0%)	80 (5.9%)	6	54	26	76	4	13	54	9	1	3	0	0
Other Non-Epithelial Skin	6 (0.4%)	5 (0.4%)	1	4	1	5	0	0	4	0	0	0	0	1
BREAST 2	218 (15.2%)	212 (15.6%)	6	3	209	202	10	36	81	54	15	10	0	16
	218 (15.2%)	212 (15.6%)	6	3	209	202	10	36	81	54	15	10	0	16
	111 (7.8%)	109 (8.0%)	2	0	109	87	22	4	46	8	30	13	2	6
Cervix Uteri	12 (0.8%)	11 (0.8%)	1	0	11	8	3	0	2	2	6	1	0	0
Corpus & Uterus, NOS Corpus Uteri	61 (4.3%) 57	60 (4.4%) 56	1	0	60 56	53 50	7 6	0	35 35	3	13 12	3 1	1	5 5
Uterus, NOS	4	4	0	0	4	3	1	0	0	1	1	2	0	0
Ovary	22( 1.5%)	22 (1.6%)	0	0	22	13	9	0	1	1	10	8	1	1
Vagina	2 (0.1%)	2 (0.1%)	0	0	2	2	0	0	0	2	0	0	0	0
Vulva	12 (0.8%)	12 (0.9%)	0	0	12	9	3	2	8	0	1	1	0	0
Other Female Genital Organs	2 (0.1%)	2 (0.1%)	0	0	2	2	0	2	0	0	0	0	0	0
MALE GENITAL SYSTEM	83 (5.8%)	77 (5.7%)	6	77	0	72	5	0	24	41	5	6	0	1
Prostate	82 (5.7%)	76 (5.6%)	6	76	0	71	5	0	24	40	5	6	0	1
Testis	1 (0.1%)	1 (0.1%)	0	61	0	70	0	0	0	10	0	0	0	0
URINARY SYSTEM Urinary Bladder	98 (6.8%) 75 (5.2%)	<b>96</b> ( <b>7.1</b> %) <b>74</b> ( <b>5.4</b> %)	2 1	50	<b>35</b> 24	<b>73</b> 54	<b>23</b> 20	<b>43</b> 42	<b>21</b>	13 10	3	<b>8</b> 5	0	7
Kidney & Renal Pelvis	21 (1.5%)	21 (1.5%)	0	10	11	18	3	1	11	2	1	3	0	3
Ureter	2 (0.1%)	1 (0.1%)	1	1	0	1	0	0	0	1	0	0	0	0
BRAIN & OTHER NERVOUS SYSTEM	25 (1.7%)	18 (1.3%)	7	7	11	12	6	0	0	0	0	0	18	o
Brain	16 (1.1%)	13 (1.0%)	3	6	7	8	5	0	0	0	0	0	13	0
Cranial Nerves Other Nervous System	9 (0.6%)	5 (0.4%)	4	1	4	4	1	0	0	0	0	0	5	0
ENDOCRINE SYSTEM	51 (3.6%)	50 (3.7%)	1	13	37	50	0	0	24	9	8	2	0	7
Thyroid	50 (3.5%)	50 (3.7%)	0	13	37	50	0	0	24	9	8	2	0	7
Other Endocrine including Thymus	1 (0.1%)	0 (0.0%)	1	0	0	0	0	0	20	0	0	0	0	0
LYMPHOMA	67 (4.7%)	62 (4.6%)	5	26	36	44	18	0	0	7	3	8	1	23
Hodgkin Lymphoma	4 (0.3%)	4 (0.3%)	0	1 25	3	4	0	0	20	1 6	0	0	0	3
Non Hodelin Lymphons	63 (4.4%)	58 (4.3%)	5	25	33	40	18	0	9	0	3	8	1	20
Non-Hodgkin Lymphoma NHL - Nodal	41	37	4	15	22	25	12	0	11	5	2	7	0	14

	Total All	Class of Case		Sex		Vital		Stage Distribution						
Primary Site	Cases (%)	Analytic (%)	NA	M	F	Alive	Exp	Stg 0	Stg I	Stg II	Stg III	Stg IV	88	Unk
	Cases (70)	Analytic (70)	INA			Analytic Cases Only								
MYELOMA	17 (1.2%)	14 (1.4%)	3	8	6	10	4	0	0	0	0	0	14	0
Myeloma	17 (1.2%)	14(1.0%)	3	8	6	10	4	0	0	0	0	0	14	0
LEUKEMIA	<b>27</b> (1. <b>9</b> %)	24 (1.8%)	3	17	7	18	6	0	0	0	0	0	24	0
Lymphocytic Leukemia	13 (0.9%)	11 (0.8%)	2	8	3	10	1	0	0	0	0	0	11	0
Chronic Lymphocytic Leukemia	8	7	1	5	2	6	1	0	0	0	0	0	7	0
Other Lymphocytic Leukemia	5	4	1	3	1	4	0	0	0	0	0	0	4	0
Myeloid & Monocytic Leukemia	13 (0.9%)	13 (1.0%)	0	9	4	8	5	0	0	0	0	0	13	0
Acute Myeloid Leukemia	10	10	0	7	3	6	4	0	0	0	0	0	10	0
Chronic Myeloid Leukemia	3	3	0	2	1	2	1	0	0	0	0	0	3	0
Other Leukemia	1 (0.1%)	0 (0.0%)	1	0	0	0	0	0	0	0	0	0	0	0
MESOTHELIOMA	6 (0.4%)	6 (0.4%)	0	5	1	5	1	0	2	0	2	0	1	1
Mesothelioma	6 (0.4%)	6 (0.4%)	0	5	1	5	1	0	2	0	2	0	- 1	1
MISCELLANEOUS	56 (3.9%)	50 (3.7%)	6	20	30	26	24	0	0	0	0	0	50	0
Miscellaneous	56 (3.9%)	50 (3.7%)	6	20	30	26	24	0	0	0	0	0	50	0

Table 1 (cont.)


**Tables 2 & 3** summarize five primary sites for 2012 by gender and compares CMC's actual cases and the estimated figures from the American Cancer Society (ACS).

MALES		
	CMC	ACS
Prostate	13%	29%
Lung	20%	14%
Colon & Rectum	12%	9%
Bladder	9%	7%
Melanoma	10%	5%


FEMALES							
	CMC	ACS					
Breast	26%	29%					
Lung	17%	14%					
Colon & Rectum	11%	9%					
Uterus	8%	6%					
Thyroid	5%	5%					

Table 2 Table 3

Figure 4 depicts age distribution in comparison with the most recent year of completed data from the National Cancer Data Base (NCDB) which is 2011. NCDB data includes 599,448 cases from 729 Comprehensive Community Cancer Program hospitals. Twenty-nine percent (29%) of patients at CMC were diagnosed between the ages of 70-79 compared to 23% at NCDB.



The American College of Surgeons requires that "unknown" stages should not exceed 10% of the site totals. CMC exceeded requirements for 2012 cases. *Figure 5* is a breakdown of stage for 5 select sites.



Percent Unknown

Lung - 8.9%

Breast - 7.5%

Colon - 2.0%

Melanoma – 0.0%

Prostate – 1.3%

Figure 5






Figure 6

